Mereo BioPharma (MREO) Receivables (2022 - 2023)
Mereo BioPharma (MREO) posted quarterly Receivables of $9.9 million for Q2 2023, up 452.55% quarter-over-quarter from $1.8 million in Q4 2022.
Mereo BioPharma (MREO) Receivables (2022 - 2023) Analysis & Trends
Mereo BioPharma (MREO) has reported Receivables for 2 consecutive years, with $9.9 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Receivables changed N/A year-over-year to $9.9 million; the TTM figure through Jun 2023 stood at $9.9 million (changed N/A YoY), while the FY2022 annual figure was $1.8 million, changed N/A from the prior year.
- Receivables grew to $9.9 million in Q2 2023 per MREO's latest filing, from $1.8 million in the prior quarter.
- Across five years, Receivables topped out at $9.9 million in Q2 2023 and bottomed at $1.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 9.88 Mn |
| Dec 31, 2022 | 1.79 Mn |